3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
9
INDUSTRY
6
NIH
2
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Recurrent Squamous Cell Lung Carcinoma
2
Melanoma
2
Hodgkin Disease
2
Thymoma
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Inoperable Åsophageal Cancer
1
Gastric and Esophagogastric Junction Adenocarcinoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
Etoposide
5
Rituximab
4
Radiotherapy
4
Methotrexate
4
Cytarabine
4
Cyclophosphamide
3
Cisplatin
3
Vincristine
2
Specimen Handling
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Methylprednisolone
2
Gemcitabine
2
Fenretinide
2
Doxorubicin
2
Carmustine
2
venetoclax
1
tucatinib
1
temsirolimus
1
plerixafor
1
pertuzumab
1
palbociclib
1
olaparib
1
merphos
1
liposomal amphotericin B
1
ixabepilone
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Lymphoma, Non-Hodgkin
×
Nivolumab
×
Clear all
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled